Literature DB >> 25189938

Executive deficit in spinocerebellar ataxia type 2 is related to expanded CAG repeats: evidence from antisaccadic eye movements.

Roberto Rodríguez-Labrada1, Luis Velázquez-Pérez2, Raúl Aguilera-Rodríguez3, Carola Seifried-Oberschmidt4, Arnoy Peña-Acosta3, Nalia Canales-Ochoa3, Jacqueline Medrano-Montero3, Annelié Estupiñan-Rodríguez3, Yaimeé Vázquez-Mojena3, Yanetza González-Zaldivar3, Jose M Laffita Mesa3.   

Abstract

Although antisaccadic task is a sensitive research tool in psychopathology, it has not been systematically studied in patients with spinocerebellar ataxia type 2 (SCA2). To identify putative biomarkers of executive dysfunction in SCA2 we assessed the antisaccade performance in 41 SCA2 patients and their sex-and-age matched controls using an electronystagmography device. We studied the relationship between findings in the antisaccade task and CAG repeat length and motor function as assessed using the Scale for the Assessment and Rating of Ataxia (SARA), Nine-Hole Pegboard Test and a validated battery for executive dysfunctions. SCA2 patients showed a significant increase of inhibition and omission antisaccadic error rates, decrease of corrected antisaccadic errors and prolongation of antisaccadic latency and antisaccadic correction latency. Multiple regression predictions identified the expanded CAG repeat as a significant contributing factor on inhibition antisaccadic error rate and percentage of corrected antisaccadic errors. Impaired antisaccadic performance was associated to higher Stroop interference task and verbal fluency test deficits. In conclusion, antisaccadic eye movement abnormalities are a newly recognized association with the genetic abnormality in SCA2 and correlate with executive dysfunction in SCA2. Antisaccade parameters are a promising source of cognitive biomarkers for exploring the disease pathophysiology, and assessing the efficacy of therapeutic options.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Antisaccades; Biomarkers; CAG repeats; Executive dysfunctions; Spinocerebellar ataxias

Mesh:

Substances:

Year:  2014        PMID: 25189938     DOI: 10.1016/j.bandc.2014.07.007

Source DB:  PubMed          Journal:  Brain Cogn        ISSN: 0278-2626            Impact factor:   2.310


  7 in total

Review 1.  Fragile X-associated tremor/ataxia syndrome: phenotypic comparisons with other movement disorders.

Authors:  Erin E Robertson; Deborah A Hall; Andrew R McAsey; Joan A O'Keefe
Journal:  Clin Neuropsychol       Date:  2016-08       Impact factor: 3.535

Review 2.  Spinocerebellar ataxias: prospects and challenges for therapy development.

Authors:  Tetsuo Ashizawa; Gülin Öz; Henry L Paulson
Journal:  Nat Rev Neurol       Date:  2018-10       Impact factor: 42.937

3.  Neuroimmunology Research. A Report from the Cuban Network of Neuroimmunology.

Authors:  María de Los Angeles Robinson-Agramonte; Lourdes Lorigados Pedre; Orlando Ramón Serrano-Barrera
Journal:  Behav Sci (Basel)       Date:  2018-05-08

Review 4.  Spinocerebellar Ataxia Type 2: Clinicogenetic Aspects, Mechanistic Insights, and Management Approaches.

Authors:  Luis C Velázquez-Pérez; Roberto Rodríguez-Labrada; Juan Fernandez-Ruiz
Journal:  Front Neurol       Date:  2017-09-11       Impact factor: 4.003

5.  Cognitive Decline Is Closely Associated with Ataxia Severity in Spinocerebellar Ataxia Type 2: a Validation Study of the Schmahmann Syndrome Scale.

Authors:  Alejandro Batista-Izquierdo; Zuleyra González-Melix; Roberto Rodríguez-Labrada; Lorenzo Reynado-Cejas; Yaimeé Vázquez-Mojena; Yuri Arsenio Sanz; Nalia Canales-Ochoa; Yanetza González-Zaldívar; Imis Dogan; Kathrin Reetz; Luis Velázquez-Pérez
Journal:  Cerebellum       Date:  2021-07-27       Impact factor: 3.847

6.  Anti-Saccades in Cerebellar Ataxias Reveal a Contribution of the Cerebellum in Executive Functions.

Authors:  Elena Pretegiani; Pietro Piu; Francesca Rosini; Pamela Federighi; Valeria Serchi; Gemma Tumminelli; Maria Teresa Dotti; Antonio Federico; Alessandra Rufa
Journal:  Front Neurol       Date:  2018-04-23       Impact factor: 4.003

Review 7.  Antisaccades in Parkinson's Disease: A Meta-Analysis.

Authors:  Josefine Waldthaler; Lena Stock; Justus Student; Johanna Sommerkorn; Stefan Dowiasch; Lars Timmermann
Journal:  Neuropsychol Rev       Date:  2021-03-19       Impact factor: 7.444

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.